I'm not sure what you are trying to say here. Yes, they don't just take random people. The breast cancer study, for example, wanted 18+ year old females, with a T1c to T3 invasive breast cancer, at any N stage, with no distant metastases, with a tumor size >1.5 cm in at least one dimension. They had to be a surgical candidate, with no chemotherapy, radiotherapy, or biologic/targeted therapy for that tumor or any other malignancy in the past 5 years. They had to have an ECOG status of 0-1, and adequate scores on several measures of organ function, and no significant heart problems or blood pressure problems.

The patients were randomly assigned to the control group or to the test group. Those in the control group were either treated with Doxorubicin/Cyclophosphamide or Docetaxel/Cyclophosphamide, randomly assigned.

Those in the test group were either treated with Doxorubicin/Cyclophosphamide or Docetaxel/Cyclophosphamide, assigned by the genomic data Potti claimed would predict which would work better for that patient.